Spots Global Cancer Trial Database for braf mutation
Every month we try and update this database with for braf mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis | NCT02537600 | Malignant Melan... | Cobimetinib + V... | 18 Years - | Center Eugene Marquis | |
| Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib | NCT03235245 | Unresectable St... Stage IV Melano... | Nivolumab + Ipi... Encorafenib + B... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma | NCT05525273 | Craniopharyngio... | Oral dabrafenib... | 18 Years - | Skane University Hospital | |
| Sequential Combo Immuno and Target Therapy (SECOMBIT) Study | NCT02631447 | Metastatic Mela... | LGX818 MEK162 Nivolumab Ipilimumab | 18 Years - | Fondazione Melanoma Onlus | |
| A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer | NCT05639413 | Metastatic Colo... BRAF V600E Muta... | Collection of b... | 18 Years - | UNICANCER | |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | NCT03333343 | EGFR-mutant Non... | EGF816 trametinib ribociclib LXH254 INC280 gefitinib | 18 Years - | Novartis | |
| Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma | NCT01611675 | Melanoma | Vemurafenib Leflunomide | 18 Years - | Massachusetts General Hospital | |
| Neoadjuvant Treatment of Colon Cancer | NCT01108107 | Colon Cancer | Oxaliplatin Capecitabine Oxaliplatin Capecitabine Panitumumab | 18 Years - | Vejle Hospital | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain | NCT01266967 | Melanoma and Br... | GSK2118436 | 18 Years - | GlaxoSmithKline | |
| Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma | NCT01611675 | Melanoma | Vemurafenib Leflunomide | 18 Years - | Massachusetts General Hospital | |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | NCT03333343 | EGFR-mutant Non... | EGF816 trametinib ribociclib LXH254 INC280 gefitinib | 18 Years - | Novartis | |
| Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer | NCT02827565 | Metastatic Colo... | KRAS, NRAS et B... | 18 Years - | Institut de Cancérologie de Lorraine | |
| Study of Vemurafenib, Carboplatin, and Paclitaxel | NCT01636622 | Advanced Cancer... | Vemurafenib Carboplatin Paclitaxel | 12 Years - | M.D. Anderson Cancer Center | |
| Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies | NCT05370469 | Lung Cancer EGFR Gene Mutat... EGFR ALK Gene Mutati... RET Gene Mutati... MET Gene Mutati... KRAS Mutation-R... BRAF ROS1 Gene Mutat... | Sensus Smartwat... RX Cap Fitbit Sense Surveys | 18 Years - | University of Virginia | |
| A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer | NCT05639413 | Metastatic Colo... BRAF V600E Muta... | Collection of b... | 18 Years - | UNICANCER | |
| Study of Vemurafenib, Carboplatin, and Paclitaxel | NCT01636622 | Advanced Cancer... | Vemurafenib Carboplatin Paclitaxel | 12 Years - | M.D. Anderson Cancer Center | |
| Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | NCT04585815 | Carcinoma, Non-... | Sasanlimab Pref... Encorafenib Binimetinib Sasanlimab Axitinib SEA-TGT | 18 Years - | Pfizer | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma | NCT05525273 | Craniopharyngio... | Oral dabrafenib... | 18 Years - | Skane University Hospital | |
| Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer | NCT01298570 | Colorectal Canc... | Regorafenib (BA... FOLFIRI Placebo FOLFIRI | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer | NCT02827565 | Metastatic Colo... | KRAS, NRAS et B... | 18 Years - | Institut de Cancérologie de Lorraine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
